BeauBrain Healthcare

BeauBrain Healthcare is a trailblazing healthcare startup dedicated to revolutionizing the treatment of Alzheimer's Disease. With a mission to introduce early intervention and personalized care in the Alzheimer's treatment landscape, the company aims to alleviate the immense pain experienced by patients and their families. With a staggering 55 million people globally affected by dementia, the prevalence of Alzheimer's Disease, as the most common form, is expected to surge with the aging population, causing substantial medical expenses and social challenges. At BeauBrain Healthcare, the approach to treatment is being transformed from "post-diagnosis treatment" to "pre-emptive intervention." The company's innovative solutions enable early disease detection through predictive analysis of specific biomarkers such as Amyloid Beta, Tau, and Neurodegeneration. Additionally, a personalized cognitive training platform (DTx) is provided. The company's ambitious objective revolves around achieving precision medicine for Alzheimer’s disease by integrating the biomarker data from its solutions with extensive genetic data. Established in 2022, BeauBrain Healthcare has already attracted attention in the investment realm, securing a Pre Seed Round investment on 17th February 2022 from MINT Venture Partners. This notable investment not only illustrates the potential of the startup but also underlines the confidence of industry players in its innovative approach to tackling Alzheimer's Disease.